West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$360.43 USD
-7.75 (-2.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $360.42 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Income Statements
Fiscal Year end for West Pharmaceutical Services, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,950 | 2,887 | 2,832 | 2,147 | 1,840 |
Cost Of Goods | 1,821 | 1,751 | 1,656 | 1,379 | 1,234 |
Gross Profit | 1,129 | 1,136 | 1,176 | 768 | 606 |
Selling & Adminstrative & Depr. & Amort Expenses | 453 | 402 | 424 | 361 | 309 |
Income After Depreciation & Amortization | 676 | 734 | 752 | 407 | 297 |
Non-Operating Income | 31 | -46 | 5 | 3 | 4 |
Interest Expense | 9 | 8 | 8 | 8 | 9 |
Pretax Income | 698 | 680 | 749 | 401 | 292 |
Income Taxes | 122 | 115 | 107 | 73 | 59 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 18 | 21 | 20 | 17 | 9 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 593 | 586 | 662 | 346 | 242 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 593 | 586 | 662 | 346 | 242 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 813 | 855 | 875 | 516 | 400 |
Depreciation & Amortization (Cash Flow) | 137 | 121 | 122 | 109 | 103 |
Income After Depreciation & Amortization | 676 | 734 | 752 | 407 | 297 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 75.30 | 75.80 | 76.30 | 75.80 | 75.40 |
Diluted EPS Before Non-Recurring Items | 8.08 | 8.58 | 8.58 | 4.76 | 3.24 |
Diluted Net EPS (GAAP) | 7.88 | 7.73 | 8.67 | 4.57 | 3.21 |
Fiscal Year end for West Pharmaceutical Services, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 732.00 | 747.40 | 753.80 | 716.60 |
Cost Of Goods | NA | 453.80 | 459.10 | 462.40 | 445.30 |
Gross Profit | NA | 278.20 | 288.30 | 291.40 | 271.30 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 117.30 | 111.00 | 108.90 | 116.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 160.90 | 177.30 | 182.50 | 155.30 |
Non-Operating Income | NA | 8.50 | 12.60 | 5.10 | 4.80 |
Interest Expense | NA | 1.20 | 2.90 | 2.70 | 2.20 |
Pretax Income | NA | 168.20 | 187.00 | 184.90 | 157.90 |
Income Taxes | NA | 34.50 | 29.40 | 34.80 | 23.60 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 3.30 | 3.70 | 5.00 | 5.70 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 137.00 | 161.30 | 155.10 | 140.00 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 137.00 | 161.30 | 155.10 | 140.00 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 75.00 | 75.30 | 75.40 | 75.70 |
Diluted EPS Before Non-Recurring Items | NA | 1.83 | 2.16 | 2.11 | 1.98 |
Diluted Net EPS (GAAP) | NA | 1.83 | 2.14 | 2.06 | 1.85 |